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selected subpopulation of 750 individuals of SHIP-TREND, 
serum 3,5-T2 concentrations were measured with a recently 
developed immunoassay. ABI was measured either by a 
hand-held Doppler ultrasound using the Huntleigh Dopplex 
D900 or palpatorily by the OMRON HEM-705CP device.  Re-
sults: Serum TSH concentrations were not significantly as-
sociated with ABI values in any of the three studies. Likewise, 
groups of individuals with a TSH <0.3 mIU/l or with a TSH 
 ≥ 3.0 mIU/l had no significantly different ABI values in com-
parison with individuals with a TSH in the reference range. 
Analyses regarding TSH within the reference range or serum 
3,5-T2 concentrations did not reveal consistent significant 
associations with the ABI. No sex-specific associations were 
detected.  Conclusions: The results of our study do not sub-
stantiate evidence for an association between thyroid func-
tion and PAD, but further studies are needed to investigate 
the associations of overt forms of thyroid dysfunction with 
PAD.  © 2015 European Thyroid Association
Published by S. Karger AG, Basel 
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 Abstract 
 Background: There is only limited data on the potential as-
sociation between thyroid dysfunction and peripheral arte-
rial disease (PAD).  Objective: The aim of our study was to 
investigate the potential association of thyroid function, as 
defined by serum concentrations of the clinically used pri-
mary thyroid function marker thyrotropin [i.e. thyroid-stim-
ulating hormone (TSH)] and 3,5-diiodothyronine (3,5-T2), 
with the ankle-brachial index (ABI) as a marker of PAD.  Meth-
ods: We used data from 5,818 individuals from three cross-
sectional population-based studies conducted in Northeast 
(SHIP-2 and SHIP-TREND) and Central Germany (CARLA). 
Measurement of serum TSH concentrations was conducted 
in one central laboratory for all three studies. In a randomly 
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 Background 
 Peripheral arterial disease (PAD) is characterized by a 
narrowing of the arterial blood vessels in the lower limb, 
which is caused by atherosclerotic processes. PAD is as-
sociated with a higher risk for cardiovascular mortality  [1, 
2] and cardiovascular events  [1, 3, 4] . A link between thy-
roid dysfunction and atherosclerotic processes has been 
previously described, pointing towards an association be-
tween hypothyroidism and atherosclerosis  [5–7] . 
 However, there is only limited data on the potential 
linkage between thyroid dysfunction and PAD as one of 
the major atherosclerotic diseases. One study reported a 
significantly higher prevalence of increased serum thy-
roid-stimulating hormone (TSH) concentrations in 30 el-
derly women with PAD in comparison to a control group 
without PAD  [8] . In contrast, a population-based study 
detected no significant association between subclinical 
hypothyroidism and PAD-related hospitalization or pro-
cedures among 2,730 elderly individuals aged 70–79 years 
 [9] . In that study, however, the direct association between 
thyroid function and ankle-brachial index (ABI) was not 
investigated.
 ABI assessed by Doppler ultrasound is the gold stan-
dard method to determine PAD  [10] . Population-based 
data on the association between thyroid dysfunction and 
PAD determined by ABI is lacking. In addition to TSH, 
3,5-diiodothyronine (3,5-T2) concentrations may also be 
related to PAD, since 3,5-T2 concentrations have been 
shown to be associated with leptin  [11] , an adipokine 
which has an impact on atherosclerotic events  [12] . Fur-
thermore, previous studies, mainly assessed in animals, 
demonstrated associations of 3,5-T2 with lipid  [13, 14] 
and glucose metabolism  [11, 15] , which are both risk fac-
tors in the pathogenesis of atherosclerosis. Therefore, the 
aim of our research was to investigate the potential asso-
ciation of thyroid function, as defined by two indepen-
dent markers of systemic and metabolic thyroid hormone 
status, i.e. the serum concentrations of TSH and 3,5-T2, 
with ABI assessed by Doppler ultrasound in three popu-
lation-based studies with 5,718 individuals in total cover-
ing an age range of 20–90 years.
 Material and Methods 
 Study Populations 
 Analyses are based on data from three population-based stud-
ies. The first two studies are separate cohorts of the Study of Health 
in Pomerania (SHIP), conducted in the same population of North-
east Germany  [16] . Initially 6,267 individuals were invited for the 
first cohort, of whom 2,333 individuals aged 30–90 years partici-
pated at the second follow-up (SHIP-2). Parallel to SHIP-2 a new 
cohort was established (SHIP-TREND) in which 8,826 individuals 
were invited and 4,420 individuals aged 20–80 years participated. 
In both studies, individuals were selected from population regis-
tries. The third study comprised data from the baseline examina-
tions of the Cardiovascular Disease, Living and Ageing in Halle 
(CARLA) study, a population-based cohort study conducted in 
Central Germany, in which 5,000 individuals were invited to par-
ticipate. Of those, 1,779 individuals aged 45–80 years were exam-
ined between 2002 and 2005  [17] . In all studies, participants gave 
informed written consent and all studies were approved by the lo-
cal ethics committees and followed the Declaration of Helsinki.
 In the two SHIP studies, all probands were invited to partici-
pate in the ABI examinations and subsamples of 1,430 (SHIP-2) 
and 2,697 individuals (SHIP-TREND) responded. To account for 
the possible selection bias according to nonparticipation in the 
ABI examination, inverse probability weights using education, 
equivalence income, blood pressure (BP), diabetes, lipids and BMI 
as explanatory variables were applied  [18] . In SHIP-2, analyses 
were additionally weighted for dropout from the baseline exami-
nation (SHIP-0) to SHIP-2. In CARLA, individuals with missing 
data in any of the considered variables (n = 106) were excluded, 
resulting in a study population of 1,691 individuals.
 Assessments 
 Blood samples were taken between 7 a.m. and 1 p.m. in the 
SHIP studies and between 7 a.m. and 7 p.m. in CARLA. All blood 
samples of the three studies were analyzed at the central labora-
tory of the University Medicine Greifswald. Serum TSH concen-
trations were measured by immunochemiluminescent procedures 
(Dimension Vista; Siemens, Eschborn, Germany) for all three 
studies. Low and high serum TSH concentrations were defined by 
the cutoffs 0.3 mIU/l and 3.0 mIU/l according to Baskin et al.  [19] . 
In a randomly selected subpopulation of 750 individuals of SHIP-
TREND, serum 3,5-T2 concentrations were measured as a poten-
tial parameter of peripheral thyroid hormone status  [20] with a 
recently developed chemiluminescent immunoassay based on 
monoclonal anti-3,5-T2 antibodies produced in mice at the Chari-
té Institute for Experimental Endocrinology  [21] . The functional 
sensitivity of the assay is specified as 0.2 n M . The interassay coef-
ficient of variation was between 12.9 and 5.6% of the linear work-
ing range of the assay.
 For ABI assessment in SHIP, systolic BP was measured with a 
‘Dopplex D900’ (Huntleigh Healthcare Ltd.) Doppler ultrasound 
probe and a BP cuff (Welch Allyn) in both arms (brachial artery) 
and both ankles (anterior and posterior tibial artery). Measure-
ments were taken in the supine position after at least 10 min of rest. 
ABI was calculated using the lower of the right and left tibial pres-
sures divided by the higher of the two brachial artery pressures.
 For ABI measurement in CARLA, the supine systolic BP at the 
arm and ankle was measured after 5 min of rest using the OMRON 
HEM-705CP device. First, a simultaneous measurement of BP at 
both arms was performed. For the BP measurements used for the 
calculation of ankle-arm index, the OMRON HEM-705CP device 
remains on the arm with the higher systolic BP. The circumference 
of both calves was determined at the midpoint of the BP cuff to 
select the adequate cuff size. The cuff was positioned approximate-
ly 5 cm above the inner ankle over the posterior tibial artery using 
the contour wrap technique. Measurement of BP was started si-
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multaneously on the arm and ankle at the same time. First, two 
measurements were performed on the right ankle, followed by two 
measurements on the left ankle. Between each pair of measure-
ments, there was a 1-min delay. To calculate ABI, the mean sys-
tolic BP of that ankle side which was lowest was divided by the 
brachial systolic BP which was the highest.
 Age, sex, smoking status, and history of myocardial infarction, 
stroke, and atrial fibrillation were assessed by computer-assisted 
personal interviews. Smokers were categorized into three catego-
ries (lifetime nonsmokers, former smokers, and current smokers).
 Statistical Analyses 
 Continuous variables were expressed as medians and 25th and 
75th percentiles; categorical variables were expressed as absolute 
numbers and percentages. Serum TSH concentrations were associ-
ated with ABI by linear regression adjusted for age, sex, and smok-
ing status, and in the SHIP studies additionally for time between 
core and ABI examination in each of the three studies separately. 
For these analyses, TSH was power-transformed to reduce the im-
pact of outliers in the TSH variable on the results  [22] . To account 
for possible nonlinear relationships between serum TSH concentra-
tions or any of the confounders with the respective outcome, frac-
tional polynomials were tested  [22] . In this analysis no nonlinear 
relationships between serum TSH concentrations and ABI were de-
tected. In SHIP, all analyses were additionally weighted for nonpar-
ticipation at the ABI examination. Inverse probability weights were 
therefore calculated by taking the inverse of the individual proba-
bilities derived from a logistic regression with participation at the 
ABI examination as the outcome and per capita income, highest 
school degree, hypertension, age, sex, diabetes mellitus type 2, BMI, 
cholesterol, and smoking status as explanatory variables. To ac-
count for a potential bias according to high ABI values due to me-
dial arteriosclerosis, we repeated all multivariable analyses under 
exclusion of individuals with ABI values >1.3 (n = 102 in SHIP-2,
n = 122 in SHIP-TREND, and n = 174 in CARLA)  [23] . p < 0.05 was 
considered statistically significant. All analyses were carried out
using Stata 13.1 (Stata Corporation, College Station, Tex., USA).
 Results 
 Description of the Study Populations 
 Individuals from CARLA were older than individuals 
from the SHIP studies ( table 1 ). In all three studies indi-
viduals with a TSH <0.3 mIU/l were in the median older 
than individuals with a TSH in the reference range. This 
difference was more pronounced in the SHIP studies than 
in CARLA. In the SHIP studies, individuals with a TSH 
 ≥ 3.0 mIU/l were in the median younger than individuals 
with a TSH in the reference range, while these two groups 
did not differ according to age in the CARLA study. In the 
SHIP studies, ABI values did not differ among groups of 
TSH, whereas in CARLA ABI values were in the median 
lower in individuals with a TSH  ≥ 3.0 mIU/l than in indi-
viduals with a TSH within the reference range. The fre-
quency of ABI <0.9 was highest in CARLA.
 Multivariable Analyses 
 Power-transformed TSH was not significantly associ-
ated with ABI in either the SHIP studies or in CARLA 
( table 2 ). Likewise, groups of individuals with a TSH <0.3 
mIU/l or with a TSH  ≥ 3.0 mIU/l had no significantly dif-
ferent ABI values compared to individuals with a TSH in 
the reference range in any of the studies. After exclusion 
of individuals with a TSH <0.3 mIU/l or with a TSH  ≥ 3.0 
mIU/l, serum TSH concentrations within the reference 
range were not significantly associated with ABI in any of 
the studies. Likewise, serum 3,5-T2 concentrations were 
not significantly associated with ABI in SHIP-TREND
(β = 0.007; 95% CI = –0.039, 0.053). We repeated these 
analyses in individuals without evidence of cardiovascu-
lar diseases (i.e. pacemaker, cardiac surgery, or history of 
myocardial infarction, stroke, or atrial fibrillation) with 
similar results compared to those among the whole popu-
lations of the single studies ( table 2 ).
 With one exception we did not detect any significant 
association between power-transformed TSH, catego-
rized TSH, or serum TSH within the reference range and 
ABI in sex-stratified analyses in SHIP-2, SHIP-TREND, 
and CARLA ( table 2 ). In males, individuals with a TSH 
 ≥ 3.0 mIU/l had significantly lower ABI than individuals 
with a TSH within the reference range in SHIP-TREND. 
In CARLA the effect size of this association was compa-
rable to the effect size in SHIP-TREND, but missed sta-
tistical significance. In SHIP-2, however, the effect size 
for this association pointed towards another direction 
and was also not statistically significant.
 In the population excluding individuals with ABI val-
ues >1.3, no substantially different results in comparison 
to those presented in  table 2 were observed.
 Discussion 
 In three population-based studies, we did not find 
consistent associations between thyroid function defined 
by serum concentrations of TSH and 3,5-T2 and ABI. 
This finding is in agreement with a population-based 
study in which serum TSH concentrations were not as-
sociated with PAD-related hospitalization and proce-
dures in individuals aged 70–79 years  [9] , but in contrast 
to a small patient study  [8] in which prevalence of in-
creased TSH was higher in elderly women with PAD than 
in those without. The major drawback of that study is that 
individuals were not randomly selected, which might 
have given rise to bias  [8] . Furthermore, no T 4 or T 3 val-
ues were determined and only 130 individuals were in-
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cluded in that study  [8] , which also hampers the general-
izability of the findings. The fact that there is only one 
small study reporting an association between thyroid 
function and PAD might argue for a lack of an association 
between thyroid hormones and PAD.
 Similarly to the results in the whole study population, 
we did not find any consistent association between serum 
TSH concentrations and ABI values when we compared 
males and females. We detected a significant association 
between increased TSH and ABI in SHIP-TREND males. 
 Table 1.  Description of the study populations stratified by serum TSH concentrations
TSH 0.3 – 3.0 mIU/l TSH <0.3 mIU/l TSH ≥3.0 mIU/l
SHIP-2
n 1,332 52 46
TSH, mIU/l 1.07 (0.75, 1.46) 0.16 (0.08, 0.22) 3.66 (3.25, 4.98)
Age, years 57 (46, 66) 64 (49, 72) 51 (45, 64)
Men 658 (49.4) 23 (44.2) 17 (37.0)
Smoking status
Former 570 (42.8) 25 (48.1) 18 (39.1)
Current 232 (17.4) 9 (17.3) 14 (30.4)
BMI 27.5 (24.8, 30.6) 27.5 (25.1, 30.7) 25.6 (23.5, 29.1)
Total cholesterol, mM 5.5 (4.8, 6.2) 5.0 (4.4, 5.7) 5.5 (4.9, 6.3)
ABI 1.13 (1.08, 1.20) 1.12 (1.07, 1.20) 1.14 (1.09, 1.20)
ABI <0.9 27 (2.0) 2 (3.9) 2 (4.4)
Systolic BP, mm Hg 132 (120, 144) 134 (114, 145) 126 (117, 143)
Diastolic BP, mm Hg 80 (74, 86) 77 (70, 85) 79 (73, 85)
SHIP-TREND
n 2,501 80 98
TSH, mIU/l 1.14 (0.79, 1.57) 0.23 (0.15, 0.27) 3.76 (3.26, 4.80)
Age, years 53 (42, 64) 59 (50, 71) 49 (37, 58)
Men 1,278 (51.1) 28 (35.0) 35 (35.7)
Smoking status
Former 973 (38.9) 39 (48.8) 13 (16.3)
Current 564 (22.6) 13 (16.3) 24 (24.5)
BMI 27.5 (24.7, 30.8) 27.7 (24.4, 31.4) 27.0 (24.2, 30.1)
Total cholesterol, mM 5.4 (4.7, 6.2) 5.5 (4.5, 6.3) 5.5 (4.8, 6.2)
ABI 1.12 (1.07, 1.18) 1.12 (1.08, 1.20) 1.11 (1.08, 1.17)
ABI <0.9 32 (1.8) 0 0
Systolic BP, mm Hg 127 (115, 139) 123 (111, 137) 122 (113, 136)
Diastolic BP, mm Hg 77 (71, 83) 74 (67, 81) 75 (70, 82)
Diiodothyronine, nM 0.24 (0.20, 0.37) 0.38 (0.20, 0.55) 0.30 (0.21, 0.39)
CARLA
n 1,446 216 29
TSH, mIU/l 0.77 (0.56, 1.09) 0.19 (0.11, 0.25) 4.01 (3.34, 6.53)
Age, years 64 (55, 73) 65 (59, 72) 65 (55, 78)
Men 807 (55.8) 103 (47.7) 10 (34.5)
Smoking status
Former 521 (36.0) 73 (33.8) 12 (41.4)
Current 639 (44.2) 108 (50.0) 13 (44.8)
BMI 27.9 (25.1, 30.9) 27.8 (25.0, 30.8) 28.6 (25.1, 30.6)
Total cholesterol, mM 5.4 (4.8, 6.2) 5.4 (4.8, 5.9) 5.5 (5.0, 6.3)
ABI 1.16 (1.08, 1.24) 1.16 (1.07, 1.23) 1.09 (1.04, 1.16)
ABI <0.9 78 (5.4) 19 (8.8) 1 (3.5)
Systolic BP, mm Hg 143 (129, 156) 141 (128, 160) 142 (134, 164)
Diastolic BP, mm Hg 85 (78, 92) 84 (77, 93) 90 (83, 94)
 Data are expressed as medians (25th and 75th percentiles) for continuous data or as absolute numbers (per-
centages) for categorical data.
 Serum Thyrotropin Concentrations Are 
Not Associated with ABI 
Eur Thyroid J 2015;4(suppl 1):101–107
DOI: 10.1159/000381309
105
However, this association was not statistically significant 
after correction for multiple testing and was also not con-
firmed by the two other studies. Thus, the detected sig-
nificant association might be a false-positive finding.
 Previous studies have shown associations of 3,5-T2 
with atherosclerotic risk factors and endpoints  [11, 13–
15, 24] . Particularly, a linkage of 3,5-T2 with lipid and 
glucose metabolism was demonstrated in animal models 
 [13–15] , which was confirmed for glucose but not for lip-
id metabolism in 1,000 humans of the SHIP-TREND 
study  [11] . In these 1,000 subjects, an association between 
3,5-T2 and retinal arteriolar narrowing, a marker of mi-
crovascular damage accompanied by media thickening 
and development of sclerotic plaques  [25] , was also dem-
onstrated. Thus, there is some evidence for an association 
between 3,5-T2 and atherosclerotic processes. However, 
in our study we could not show an association between 
3,5-T2 and PAD, which in addition to the null finding for 
serum TSH concentrations argues for a lack of an asso-
ciation between thyroid hormones and PAD.
 It has to be stressed that the number of individuals 
with overt forms of thyroid dysfunction was low in SHIP-
2, SHIP-TREND, and CARLA. In CARLA only 13% of all 
individuals with decreased serum TSH concentrations 
had increased serum free triiodothyronine (fT 3 ) or in-
creased free thyroxine concentrations (fT 4 ), while only 5 
of the 29 individuals with increased serum TSH concen-
trations had decreased concentrations of fT 3 or fT 4 . In the 
 Table 2.  Association between serum TSH concentrations and ABI
ABI – total population ABI – population without prevalent cardiovascular 
events
SHIP-2 SHIP-TREND CARLA SHIP-2 SHIP-TREND CARLA
Males and females
PTSH –0.044 
(–0.105, 0.017)
–0.014 
(–0.048, 0.019)
0.018 
(–0.024, 0.059)
–0.031 
(–0.087, 0.026)
–0.014 
(–0.048, 0.021)
0.007 
(–0.034, 0.048)
TSH <0.3 mIU/la –0.005 
(–0.043, 0.034)
0.010 
(–0.013, 0.034)
–0.006 
(–0.024, 0.012)
0.006 
(–0.027, 0.039)
0.002 
(–0.022, 0.026)
–0.003 
(–0.021, 0.016)
TSH ≥3 mIU/la –0.010 
(–0.058, 0.038)
–0.005 
(–0.021, 0.011)
–0.021 
(–0.068, 0.025)
–0.003 
(–0.049, 0.042)
–0.008 
(–0.025, 0.009)
–0.025 
(–0.071, 0.021)
TSH within the 
reference range
–0.013 
(–0.027, 0.002)
–0.001 
(–0.009, 0.007)
0.010 
(–0.003, 0.023)
–0.008 
(–0.022, 0.006)
–0.001 
(–0.008, 0.007)
0.008 
(–0.005, 0.021)
Males
PTSH –0.018 
(–0.098, 0.062)
–0.036 
(–0.097, 0.025)
0.037 
(–0.029, 0.104)
0.006 
(–0.071, 0.083)
–0.032 
(–0.094, 0.031)
0.018 
(–0.048, 0.084)
TSH <0.3 mIU/la 0.007 
(–0.039, 0.054)
0.026 
(–0.016, 0.067)
–0.027 
(–0.056, 0.001)
0.006 
(–0.043, 0.056)
0.015 
(–0.032, 0.061)
–0.022 
(–0.051, 0.007)
TSH ≥3 mIU/la 0.030 
(–0.018, 0.079)
–0.024 
(–0.052, 0.003)
–0.009 
(–0.095, 0.077)
0.038 
(–0.010, 0.086)
–0.029 
(–0.058, –0.001)*
–0.022 
(–0.108, 0.064)
TSH within the 
reference range
–0.011 
(–0.033, 0.011)
0.001 
(–0.014, 0.012)
0.006 
(–0.014, 0.026)
–0.007 
(–0.028, 0.014)
0.002 
(–0.012, 0.015)
0.003 
(–0.016, 0.023)
Females
PTSH –0.059 
(–0.146, 0.029)
–0.005 
(–0.042, 0.031)
0.002 
(–0.049, 0.052)
–0.058 
(–0.137, 0.022)
–0.006 
(–0.045, 0.032)
–0.006 
(–0.058, 0.045)
TSH <0.3 mIU/la –0.017 
(–0.073, 0.040)
0.005 
(–0.023, 0.033)
0.015 
(–0.007, 0.038)
0.006 
(–0.038, 0.050)
–0.002 
(–0.030, 0.026)
0.017 
(–0.006, 0.040)
TSH ≥3 mIU/la –0.035 
(–0.104, 0.036)
0.003 
(–0.015, 0.022)
–0.024 
(–0.076, 0.027)
–0.031 
(–0.099, 0.036)
0.001 
(–0.019, 0.021)
–0.026 
(–0.077, 0.025)
TSH within the 
reference range
–0.012 
(–0.031, 0.007)
–0.002 
(–0.011, 0.006)
0.015 
(–0.002, 0.033)
–0.010 
(–0.029, 0.008)
–0.003 
(–0.012, 0.006)
0.013 
(–0.005, 0.031)
 Data are expressed as linear regression β (95% CI). All analyses were adjusted for age, sex, and smoking status, and in the SHIP stud-
ies for the time between core and ABI examinations. PTSH = Power-transformed TSH. * p < 0.05. a Reference: TSH in the reference 
range. 
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two SHIP studies, fT 3 and fT 4 were not measured, but 
data from the baseline examination of SHIP-2 points to-
wards a low prevalence of overt thyroid dysfunction in 
SHIP  [26] . Thus, we are not able to draw conclusions 
from our study about the hypothetical association be-
tween overt forms of thyroid dysfunction and PAD. Like-
wise, the number of individuals with ABI <0.9, which is 
an accepted clinical cutoff for diagnosis of PAD  [27] , was 
low in the three considered studies and, thus, power was 
not sufficient to investigate the association between se-
rum TSH concentrations and ABI <0.9.
 The main strength of our study is that we used data 
from three population-based studies from two different 
regions in Germany with 5,718 individuals in total. Thus, 
our results are generalizable to the background popula-
tion of Germany. However, in the SHIP studies, only a 
subsample participated at the ABI examination, but we 
applied inverse probability weights to minimize potential 
selection bias. Another drawback of our study was the 
nonavailability of fT 3 and fT 4 measurements which fol-
lowed guideline recommendations to determine serum 
TSH as baseline parameter of thyroid function in healthy 
individuals. Thus, we were not able to study the potential 
associations of serum fT 4 and fT 3 concentrations with 
PAD, which would have given more detailed information 
on the association between thyroid function and PAD. In 
SHIP-TREND, however, we detected no significant asso-
ciation between 3,5-T2, which is at least considered to 
represent partially a degradation product of T 3 and T 4 , 
and PAD. This may argue for the lack of an association 
between thyroid function and PAD. A further limitation 
might be that different methods were used in CARLA and 
SHIP for the assessment of ABI.
 In conclusion, the results of our study do not substan-
tiate evidence for an association between thyroid func-
tion and PAD, but further studies are warranted to inves-
tigate the associations of overt forms of thyroid dysfunc-
tion and PAD.
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